AU706591B2 - Nitric oxide donors capable of reducing toxicity from drugs - Google Patents
Nitric oxide donors capable of reducing toxicity from drugs Download PDFInfo
- Publication number
- AU706591B2 AU706591B2 AU20924/97A AU2092497A AU706591B2 AU 706591 B2 AU706591 B2 AU 706591B2 AU 20924/97 A AU20924/97 A AU 20924/97A AU 2092497 A AU2092497 A AU 2092497A AU 706591 B2 AU706591 B2 AU 706591B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- drugs
- chosen
- compounds
- vehicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 239000002840 nitric oxide donor Substances 0.000 title claims description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title abstract description 14
- 231100000419 toxicity Toxicity 0.000 title abstract description 9
- 230000001988 toxicity Effects 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 230000002496 gastric effect Effects 0.000 claims abstract description 15
- 150000002484 inorganic compounds Chemical class 0.000 claims abstract description 5
- 229910010272 inorganic material Inorganic materials 0.000 claims abstract description 5
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 22
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 20
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 17
- 229960004316 cisplatin Drugs 0.000 claims description 17
- 239000000006 Nitroglycerin Substances 0.000 claims description 16
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 14
- 229960001259 diclofenac Drugs 0.000 claims description 12
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 12
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 11
- 229930105110 Cyclosporin A Natural products 0.000 claims description 11
- 108010036949 Cyclosporine Proteins 0.000 claims description 11
- 229960001265 ciclosporin Drugs 0.000 claims description 11
- 229930182912 cyclosporin Natural products 0.000 claims description 11
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 9
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 9
- 229960004150 aciclovir Drugs 0.000 claims description 9
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 9
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 7
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 7
- 230000000259 anti-tumor effect Effects 0.000 claims description 7
- 229960001680 ibuprofen Drugs 0.000 claims description 7
- 229960000905 indomethacin Drugs 0.000 claims description 7
- 229960004584 methylprednisolone Drugs 0.000 claims description 7
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 6
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 6
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 6
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 6
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 6
- 230000000043 immunodepressive effect Effects 0.000 claims description 6
- 229960002009 naproxen Drugs 0.000 claims description 6
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 6
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims description 6
- 230000003637 steroidlike Effects 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960002497 nicorandil Drugs 0.000 claims description 4
- 231100000828 respiratory toxicity Toxicity 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 claims description 3
- 229940127217 antithrombotic drug Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- SUAJWTBTMNHVBZ-UHFFFAOYSA-N clonitrate Chemical compound [O-][N+](=O)OCC(CCl)O[N+]([O-])=O SUAJWTBTMNHVBZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229950004347 clonitrate Drugs 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 229960005450 eritrityl tetranitrate Drugs 0.000 claims description 2
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960004369 flufenamic acid Drugs 0.000 claims description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 2
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 claims description 2
- 229960000588 flunixin Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical compound O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004752 ketorolac Drugs 0.000 claims description 2
- DGMJZELBSFOPHH-KVTDHHQDSA-N mannite hexanitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)CO[N+]([O-])=O DGMJZELBSFOPHH-KVTDHHQDSA-N 0.000 claims description 2
- 229960001765 mannitol hexanitrate Drugs 0.000 claims description 2
- 229960003464 mefenamic acid Drugs 0.000 claims description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 2
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 229960000916 niflumic acid Drugs 0.000 claims description 2
- -1 nitroderivative com- pounds Chemical class 0.000 claims description 2
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229960002485 trolnitrate Drugs 0.000 claims description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 101100184147 Caenorhabditis elegans mix-1 gene Proteins 0.000 claims 1
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 3
- 150000002894 organic compounds Chemical class 0.000 abstract description 3
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 abstract description 2
- 210000003038 endothelium Anatomy 0.000 abstract description 2
- 229910004679 ONO2 Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 229940109239 creatinine Drugs 0.000 description 16
- 238000007920 subcutaneous administration Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 14
- 238000011534 incubation Methods 0.000 description 13
- 238000007912 intraperitoneal administration Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 10
- BQMKAHQKDSZAIQ-UHFFFAOYSA-N tetrasodium;iron(3+);nitroxyl anion;pentacyanide Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] BQMKAHQKDSZAIQ-UHFFFAOYSA-N 0.000 description 10
- 108010061435 Enalapril Proteins 0.000 description 8
- 229960000873 enalapril Drugs 0.000 description 8
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- 229960002504 capsaicin Drugs 0.000 description 7
- 235000017663 capsaicin Nutrition 0.000 description 7
- 150000002828 nitro derivatives Chemical class 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 206010006482 Bronchospasm Diseases 0.000 description 5
- 241000700198 Cavia Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 230000007885 bronchoconstriction Effects 0.000 description 5
- 238000013222 sprague-dawley male rat Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 235000007836 Chlorogalum pomeridianum Nutrition 0.000 description 3
- 240000006670 Chlorogalum pomeridianum Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- AKFJWRDCWYYTIG-ZDUSSCGKSA-N naproxcinod Chemical compound C1=C([C@H](C)C(=O)OCCCCO[N+]([O-])=O)C=CC2=CC(OC)=CC=C21 AKFJWRDCWYYTIG-ZDUSSCGKSA-N 0.000 description 3
- 206010034674 peritonitis Diseases 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011886 postmortem examination Methods 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-M 2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=C(C(C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-M 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 description 1
- 229950006286 pentrinitrol Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960005335 propanol Drugs 0.000 description 1
- YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 description 1
- 229960003402 propatylnitrate Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Underground Structures, Protecting, Testing And Restoring Foundations (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI96A000352 | 1996-02-26 | ||
| IT96MI000352A IT1282686B1 (it) | 1996-02-26 | 1996-02-26 | Composti in grado di ridurre la tossicita' da farmaci |
| PCT/EP1997/000873 WO1997031654A1 (en) | 1996-02-26 | 1997-02-24 | Nitric oxide donors capable of reducing toxicity from drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2092497A AU2092497A (en) | 1997-09-16 |
| AU706591B2 true AU706591B2 (en) | 1999-06-17 |
Family
ID=11373387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU20924/97A Ceased AU706591B2 (en) | 1996-02-26 | 1997-02-24 | Nitric oxide donors capable of reducing toxicity from drugs |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7087588B2 (en, 2012) |
| EP (2) | EP0904110B1 (en, 2012) |
| JP (1) | JP2000506133A (en, 2012) |
| KR (1) | KR19990087113A (en, 2012) |
| AT (1) | ATE220920T1 (en, 2012) |
| AU (1) | AU706591B2 (en, 2012) |
| BR (1) | BR9707739A (en, 2012) |
| CA (1) | CA2247848C (en, 2012) |
| DE (1) | DE69714253T2 (en, 2012) |
| DK (1) | DK0904110T3 (en, 2012) |
| ES (1) | ES2180938T3 (en, 2012) |
| HU (1) | HUP9900993A3 (en, 2012) |
| IT (1) | IT1282686B1 (en, 2012) |
| PT (1) | PT904110E (en, 2012) |
| RU (1) | RU2192247C2 (en, 2012) |
| WO (1) | WO1997031654A1 (en, 2012) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US6043232A (en) * | 1997-07-23 | 2000-03-28 | Nitromed, Inc. | Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs |
| GB9801398D0 (en) | 1998-01-22 | 1998-03-18 | Anggard Erik E | Chemical compounds |
| IT1298338B1 (it) * | 1998-03-05 | 1999-12-20 | Nicox Sa | Composizioni farmaceutiche per l'ulcera |
| JP2002528495A (ja) | 1998-10-30 | 2002-09-03 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化された非ステロイド抗炎症性化合物、組成物および使用方法 |
| TWI243672B (en) * | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
| US6436990B1 (en) | 1999-10-27 | 2002-08-20 | Nobex Corporation | 6-methoxy-2-naphthylacetic acid prodrugs |
| TWI262791B (en) | 1999-10-27 | 2006-10-01 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
| US6552078B2 (en) | 1999-10-27 | 2003-04-22 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
| BR0017037A (pt) | 1999-12-23 | 2003-06-10 | Nitromed Inc | Inibidores de ciclooxigenase-2 nitrosados e nitrosilados, composições e métodos de uso |
| US7018979B1 (en) | 2000-01-26 | 2006-03-28 | Cedars-Sinai Medical Center | Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| AU2001234602A1 (en) * | 2000-01-26 | 2001-08-07 | Cedars-Sinai Medical Center | Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor |
| US6706724B2 (en) | 2000-12-21 | 2004-03-16 | Nitromed, Inc. | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| EP1219306A1 (en) * | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
| US7211561B2 (en) | 2001-10-12 | 2007-05-01 | Cedars-Sinai Medical Center | Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa) |
| EP1503754B1 (en) | 2002-04-19 | 2005-11-23 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
| US7220749B2 (en) | 2002-06-11 | 2007-05-22 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| CA2492066A1 (en) | 2002-06-28 | 2004-01-08 | Nitromed, Inc. | Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| EP1539729A4 (en) | 2002-07-03 | 2008-02-20 | Nitromed Inc | NITROSED NON-TESTED OXIDE COMPOUNDS, COMPOSITIONS, AND APPLICATION METHODS |
| US7244753B2 (en) | 2002-07-29 | 2007-07-17 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| SE0300971D0 (sv) * | 2003-04-03 | 2003-04-03 | Aga Ab | Nitric oxide in treatment of inflammation |
| WO2005070868A1 (en) * | 2004-01-27 | 2005-08-04 | Merck Frosst Company | Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events |
| US20080039521A1 (en) * | 2004-06-10 | 2008-02-14 | Hiroyasu Yasuda | Anticancer Effect Enhancer |
| JP2007325501A (ja) * | 2004-08-25 | 2007-12-20 | Tottori Univ | 非ステロイド性抗炎症薬による動物の消化管副作用の予防・治療方法 |
| JP5274248B2 (ja) | 2005-05-27 | 2013-08-28 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子 |
| US20100240745A1 (en) * | 2009-03-20 | 2010-09-23 | Nicox S.A. | Method of treatment of inflammation in hypertensive patients |
| CN102695528B (zh) | 2009-08-21 | 2016-07-13 | 诺万公司 | 创伤敷料、其使用方法及其形成方法 |
| US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| EP2681286B1 (en) | 2011-02-28 | 2018-08-15 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
| JO3350B1 (ar) | 2011-03-07 | 2019-03-13 | Merck Sharp & Dohme | مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات |
| RU2539630C1 (ru) * | 2013-07-09 | 2015-01-20 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемии сетчатки в эксперименте |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5570683A (en) | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
| IT1256345B (it) | 1992-08-20 | 1995-12-01 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| IT1256450B (it) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
| BR9407749A (pt) | 1993-10-06 | 1997-02-12 | Nicox Sa | Derivados de ácido processo para a preparaçao dos mesmos e composiçoes farmacêuticas |
| US5861426A (en) | 1994-05-10 | 1999-01-19 | Nicox S.A. | Nitro compounds of the formula A-Xi -NO2 and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities |
| US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US5620416A (en) | 1995-06-07 | 1997-04-15 | North Carolina State University | Methods of using topical agents with systemically administered active agents |
-
1996
- 1996-02-26 IT IT96MI000352A patent/IT1282686B1/it active IP Right Grant
-
1997
- 1997-02-24 ES ES97906115T patent/ES2180938T3/es not_active Expired - Lifetime
- 1997-02-24 AU AU20924/97A patent/AU706591B2/en not_active Ceased
- 1997-02-24 DK DK97906115T patent/DK0904110T3/da active
- 1997-02-24 RU RU98117618/14A patent/RU2192247C2/ru not_active IP Right Cessation
- 1997-02-24 DE DE69714253T patent/DE69714253T2/de not_active Revoked
- 1997-02-24 EP EP97906115A patent/EP0904110B1/en not_active Revoked
- 1997-02-24 EP EP02008079A patent/EP1221326A3/en not_active Withdrawn
- 1997-02-24 CA CA002247848A patent/CA2247848C/en not_active Expired - Fee Related
- 1997-02-24 WO PCT/EP1997/000873 patent/WO1997031654A1/en not_active Application Discontinuation
- 1997-02-24 BR BR9707739A patent/BR9707739A/pt not_active Application Discontinuation
- 1997-02-24 PT PT97906115T patent/PT904110E/pt unknown
- 1997-02-24 AT AT97906115T patent/ATE220920T1/de not_active IP Right Cessation
- 1997-02-24 JP JP9530576A patent/JP2000506133A/ja active Pending
- 1997-02-24 KR KR1019980706501A patent/KR19990087113A/ko not_active Ceased
- 1997-02-24 HU HU9900993A patent/HUP9900993A3/hu unknown
-
2004
- 2004-07-07 US US10/885,121 patent/US7087588B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI960352A0 (en, 2012) | 1996-02-26 |
| RU2192247C2 (ru) | 2002-11-10 |
| ATE220920T1 (de) | 2002-08-15 |
| PT904110E (pt) | 2002-12-31 |
| ITMI960352A1 (it) | 1997-08-26 |
| US20040242651A1 (en) | 2004-12-02 |
| WO1997031654A1 (en) | 1997-09-04 |
| CA2247848A1 (en) | 1997-09-04 |
| HUP9900993A2 (hu) | 1999-09-28 |
| AU2092497A (en) | 1997-09-16 |
| DK0904110T3 (da) | 2002-11-11 |
| BR9707739A (pt) | 1999-07-27 |
| ES2180938T3 (es) | 2003-02-16 |
| JP2000506133A (ja) | 2000-05-23 |
| EP0904110B1 (en) | 2002-07-24 |
| KR19990087113A (ko) | 1999-12-15 |
| US7087588B2 (en) | 2006-08-08 |
| CA2247848C (en) | 2008-07-15 |
| DE69714253D1 (de) | 2002-08-29 |
| EP1221326A3 (en) | 2004-01-14 |
| IT1282686B1 (it) | 1998-03-31 |
| EP0904110A1 (en) | 1999-03-31 |
| HUP9900993A3 (en) | 2000-10-30 |
| DE69714253T2 (de) | 2003-03-06 |
| EP1221326A2 (en) | 2002-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU706591B2 (en) | Nitric oxide donors capable of reducing toxicity from drugs | |
| Fiorucci et al. | Nitric Oxide—Releasing NSAIDs: A Review of Their Current Status | |
| US6265420B1 (en) | Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide | |
| ES2215305T3 (es) | Metodos analgesicos usando los catalizadores sinteticos para la dismutacion de los radicales superoxido. | |
| US6057367A (en) | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses | |
| US4933324A (en) | Fatty acid-neuroactive drug conjugate as a prodrug | |
| US5266594A (en) | Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity | |
| RU98117618A (ru) | Донорные окиси азота, способные снижать токсичность от лекарственных препаратов | |
| GB2046094A (en) | Stabilized parenterally administrable solutions | |
| AU679492B2 (en) | Methods for the improvement of cognition with functional antagonists of the glycine NMDA receptor complex | |
| EP0109036B1 (en) | Anti-inflammatory/analgesic combination of alpha-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (nsaid) | |
| Snoj et al. | Phospholipase-resistant phosphatidylcholine reduces intra-abdominal adhesions induced by bacterial peritonitis | |
| Graham et al. | The cellular metabolism and effects of gold complexes | |
| EP0669824B1 (en) | Use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension | |
| Larsen et al. | Antileukotriene therapy for asthma | |
| JPS5829708A (ja) | 痙「れん」 | |
| JPH0314812B2 (en, 2012) | ||
| Whittle | Nitric oxide and the gut injury induced by non-steroidal anti-inflammatory drugs | |
| ES2203603T3 (es) | Composicion de sulfoxido de tiocarbamato para disuadir la ingestion de etanol. | |
| Rand et al. | AND ENTERIC NERVOUS SYSTEMS | |
| Hascelik et al. | Effects of tenoxicam on neutrophil chemotaxis in rheumatoid arthritis and healthy controls | |
| Reimann | Cutaneous manifestations of periodic diseases. | |
| EP1616564A2 (en) | Manipulation of nitrosative stress for treating microbes and helminths | |
| EP0009046A1 (en) | Composition containing salicylsalicyclic acid and acetaminophen | |
| WO1993008801A1 (en) | Prevention of drug-induced agranulocytosis with free radical scavengers |